title: L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study.
abstract: BACKGROUND
  L-Arginine is the precursor of endogenous nitric oxide (NO), which is a potent vasodilator acting via the intracellular second-messenger cGMP. In healthy humans, L-arginine induces peripheral vasodilation and inhibits platelet aggregation due to an increased NO production. Prostaglandin E1 (PGE1) induces peripheral vasodilation via stimulating prostacyclin receptors.
  
  
  RESULTS
  We investigated the effects of one intravenous infusion of L-arginine (30 g, 60 minutes) or PGE1 (40 microgram, 60 minutes) versus those of placebo (150 mL 0.9% saline, 60 minutes) on blood pressure, peripheral hemodynamics, and urinary NO3- and cGMP excretion rates in patients with critical limb ischemia (peripheral arterial occlusive disease stages Fontaine III or IV). Blood flow in the femoral artery was significantly increased by L-arginine (+42.3 +/- 7.9%, P<.05) and by PGE1 (+31.0 +/- 10.2%, P<.05) but not by placebo (+4.3 +/- 13.0%, P=NS). Urinary NO3- excretion increased by 131.8 +/- 39.5% after L-arginine (P<.05) but only by 32.3 +/- 17.2% after PGE1 (P=NS). Urinary cGMP excretion increased by 198.7 +/- 84.9% after L-arginine (P<.05) and by 94.2 +/- 58.8% after PGE1 (P=NS). Both urinary index metabolites were unchanged by placebo.
  
  
  CONCLUSIONS
  We conclude that intravenous L-arginine induces NO-dependent peripheral vasodilation in patients with critical limb ischemia. These effects are paralleled by increased urinary NO3- and cGMP excretion, indicating an enhanced systemic NO production. Increased urinary NO3- excretion may be a sum effect of NO synthase substrate provision (L-arginine) and increased shear stress (PGE1 and L-arginine).
authors.affiliation: Institute of Clinical Pharmacology, Medical School, Hannover, Germany.
authors.forename: S M
authors.initials: SM
authors.lastname: Bode-Böger
authors.forename: R H
authors.initials: RH
authors.lastname: Böger
authors.forename: H
authors.initials: H
authors.lastname: Alfke
authors.forename: D
authors.initials: D
authors.lastname: Heinzel
authors.forename: D
authors.initials: D
authors.lastname: Tsikas
authors.forename: A
authors.initials: A
authors.lastname: Creutzig
authors.forename: K
authors.initials: K
authors.lastname: Alexander
authors.forename: J C
authors.initials: JC
authors.lastname: Frölich
mesh_terms: D000368:Aged; D001120:Arginine / Q000627:therapeutic use*; D001157:Arterial Occlusive Diseases / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005121:Extremities / Q000098:blood supply*; D006801:Humans; D007275:Injections, Intravenous; D007511:Ischemia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000378:metabolism*; D014664:Vasodilation / Q000187:drug effects*
chemical_list: D009569:Nitric Oxide; D001120:Arginine